Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Pappas Capital is a global venture capital and commercial development firm founded in 1994 and based in Durham, North Carolina. The firm has over 31 years of experience in investing in next-generation life science, agriculture, and technology companies. Pappas Capital operates three primary lines of business: Pappas Ventures, which serves as its flagship life science venture arm; Specialized Fund Management, which creates and manages customized investment vehicles; and Translational Medicine, which collaborates with academic institutions to accelerate scientific discoveries.
Currently, Pappas Capital manages a diverse portfolio of over 100 companies, focusing on enhancing patient outcomes and delivering substantial returns to investors. The firm has established a strong presence in the United States, Canada, and Asia, leveraging its extensive network and expertise in the life sciences sector. Notable milestones include partnerships with leading academic institutions and significant investments in innovative healthcare solutions.
Pappas Capital invests primarily in the life sciences sector, including biotechnology, biopharmaceuticals, drug delivery, and medical devices. The firm targets opportunities across various stages, from seed stage to later-stage mezzanine transactions, with a particular interest in companies at Phase 1 or Phase 2 of development. Pappas Capital emphasizes strong proprietary positions, well-defined markets, and effective management teams as key criteria for investment.
The firm operates three distinct lines of business: Pappas Ventures focuses on funding innovative life science companies; Specialized Fund Management structures customized investment vehicles tailored to specific needs; and Translational Medicine partners with academic institutions to facilitate the translation of scientific research into viable products. This multifaceted approach allows Pappas Capital to maintain a competitive edge in the rapidly evolving healthcare landscape.
Pappas Capital has invested in over 100 companies, showcasing a diverse portfolio in the healthcare and biotechnology sectors. Notable portfolio companies include:
This extensive portfolio reflects Pappas Capital's commitment to advancing healthcare through strategic investments in innovative companies.
Art Pappas: Founder and Managing Partner. Art has extensive experience in venture capital and has led numerous successful investments in the life sciences sector.
Nikki Heron: Chief Financial Officer. Nikki oversees financial operations and has a strong background in finance and investment management.
Drew Cutshaw, MD: Principal and Medical Officer. Drew brings medical expertise to the team, focusing on evaluating healthcare investments.
Phillip Graham: Principal. Phillip has a background in venture capital and has been involved in various successful investments.
Tom Mathers: Partner. Tom has extensive experience in the life sciences sector and plays a key role in investment strategy.
Richard Pascoe: Senior Advisor. Richard provides strategic insights and guidance based on his extensive industry experience.
Charles Gersbach, PhD: Scientific Advisory Board. Charles contributes scientific expertise, particularly in biotechnology and life sciences.
Rodolphe Barrangou, PhD: Scientific Advisory Board. Rodolphe offers insights into genetic engineering and biotechnology innovations.
Startups interested in pitching to Pappas Capital should reach out through their website. A detailed pitch deck should include information about the business model, market analysis, competitive landscape, and team qualifications. The firm prefers warm introductions but is open to direct submissions.
Response times may vary, but founders can expect to hear back within a few weeks after submission. It is advisable to follow up if no response is received within that timeframe.
Pappas Capital operates the Wake Forest Technology Development Program, a partnership with Wake Forest University aimed at accelerating the development of innovative life science technologies. The firm has committed $15 million to support 25 to 30 technologies over four to five years, providing a structured approach to fostering innovation in the life sciences sector.
Recently, Pappas Capital has been active in the market, highlighting significant developments within its portfolio. Notably, Aktis Oncology completed its initial public offering, marking a significant milestone for the firm. Additionally, Cadrenal Therapeutics announced the acquisition of a new therapeutic asset, showcasing ongoing engagement with their portfolio companies.
These developments reflect Pappas Capital's commitment to supporting its investments and staying involved in the broader life sciences community. The firm continues to publish updates and insights regarding its portfolio and industry trends through its website.
What are Pappas Capital's investment criteria?
Pappas Capital focuses on innovative life science, agriculture, and technology companies. They look for strong proprietary positions, well-defined markets, and effective management teams. The firm invests across various stages, particularly favoring companies in Phase 1 or Phase 2 of development.
How can startups apply or pitch to Pappas Capital?
Startups interested in pitching to Pappas Capital should prepare a comprehensive presentation that outlines their business model, market opportunity, and management team. Direct outreach through their website is encouraged, and warm introductions are preferred.
What makes Pappas Capital different from other venture firms?
Pappas Capital distinguishes itself through its strong emphasis on life sciences and biotechnology sectors, along with its established partnerships with academic institutions. This allows them to facilitate the translation of scientific research into viable products, enhancing their investment strategy.
What is the geographic scope of Pappas Capital's investments?
The firm invests primarily in the United States, Canada, and Asia, focusing on companies that align with their investment thesis in life sciences and technology.
What is the typical check size for investments?
Pappas Capital invests across various stages, with check sizes varying based on the specific needs of the company and the stage of development. They are known to participate in seed stage to later-stage mezzanine transactions.
What kind of post-investment involvement does Pappas Capital have?
Pappas Capital actively engages with its portfolio companies, providing operational support, strategic guidance, and access to their extensive network. They often take board positions to ensure alignment and support for growth.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.